Increased oro-cecal transit time in grade I or II hepatic encephalopathy

Gastroenterol Clin Biol. 2004 Dec;28(12):1240-4. doi: 10.1016/s0399-8320(04)95217-7.

Abstract

The pathogenic mechanisms of hepatic encephalopathy remain to be elucidated. It has been suggested that a digestive motor disorder could promote the absorption of toxins produced within the lumen and thus enhance hepatic encephalopathy.

Aim: To evaluate oro-cecal transit time in cirrhotic patients with and without hepatic encephalopathy.

Methods: Hospitalized patients with alcoholic cirrhosis without encephalopathy and with spontaneous grade I and II encephalopathy were included. Severity of hepatic encephalopathy was assessed clinically and the Child-Pugh score was used to describe cirrhosis severity. Nine healthy volunteers constituted a control group. Oro-cecal transit time was measured with the sulfasalazine test.

Results: Twenty-eight patients (mean age 62.5 +/- 8.5 years) were included. Ten had hepatic encephalopathy of unknown cause and 18 were free of hepatic encephalopathy. Oro-cecal transit time was significantly longer in patients with hepatic encephalopathy (641 +/- 350 min) compared to patients without hepatic encephalopathy (298 +/- 96; P<0.05) and to controls (354 +/- 90; P<0.05). Oro-cecal transit time was comparable for each Child-Pugh score and was not different between the two grades of hepatic encephalopathy.

Conclusion: Oro-cecal transit time is longer in alcoholic cirrhosis patients with hepatic encephalopathy. This digestive motor disorder provides a partial explanation of hepatic encephalopathy of unknown etiology.

MeSH terms

  • Case-Control Studies
  • Female
  • Gastrointestinal Agents / blood
  • Gastrointestinal Agents / pharmacokinetics
  • Gastrointestinal Transit / physiology*
  • Hepatic Encephalopathy / classification
  • Hepatic Encephalopathy / complications
  • Hepatic Encephalopathy / physiopathology*
  • Humans
  • Liver Cirrhosis, Alcoholic / complications
  • Liver Cirrhosis, Alcoholic / physiopathology*
  • Male
  • Middle Aged
  • Prospective Studies
  • Severity of Illness Index
  • Sulfasalazine / blood
  • Sulfasalazine / pharmacokinetics

Substances

  • Gastrointestinal Agents
  • Sulfasalazine